Invention Grant
- Patent Title: Cancer starvation therapy
-
Application No.: US14860204Application Date: 2015-09-21
-
Publication No.: US10292956B2Publication Date: 2019-05-21
- Inventor: Pedro Anastacio Serrano-Ojeda
- Applicant: Pedro Anastacio Serrano-Ojeda
- Applicant Address: US PR Bayamon
- Assignee: Serbig Pharmaceutics Corp.
- Current Assignee: Serbig Pharmaceutics Corp.
- Current Assignee Address: US PR Bayamon
- Agency: Hogan Lovells US LLP
- Main IPC: A61K31/07
- IPC: A61K31/07 ; A61K31/14 ; A61K31/19 ; A61K31/51 ; A61K33/06 ; A61K33/18 ; A61K36/28 ; A61K39/00 ; A61K31/122 ; A61K31/194 ; A01N43/00 ; A01N43/46 ; A61K31/55 ; A61K31/198 ; A61K31/28 ; A61N5/10 ; A61N5/02 ; A61K41/00 ; C07F1/00 ; A61K47/54 ; A61K31/197 ; A61K31/355 ; A61K31/375 ; A61K31/455 ; A61K31/519 ; A61K31/525 ; A61K31/555 ; A61K31/593 ; A61K31/714 ; A61K31/4415

Abstract:
The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
Public/Granted literature
- US20160058728A1 CANCER STARVATION THERAPY Public/Granted day:2016-03-03
Information query